M Rieger1, A Österborg2, R Pettengell3, D White4, D Gill5, J Walewski6, E Kuhnt7, M Loeffler8, M Pfreundschuh9, A D Ho10. 1. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany. Electronic address: michael.rieger@med.uni-heidelberg.de. 2. Departments of Oncology, Haematology, Karolinska University Hospital, Stockholm, Sweden. 3. St George's University of London, UK. 4. Dalhousie University, Halifax, Nova Scotia for the NCIC Clinical Trials Group, Kingston, Ontario, Canada. 5. Department of Haematology, Princess Alexandra Hospital, Queensland, Australia. 6. Department of Lymphoma, Maria Sklodowska-Curie Institute and Oncology Centre, Warszawa, Poland. 7. Clinical Trial Centre Leipzig, University of Leipzig, Leipzig. 8. Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig. 9. Saarland University Medical School, Homburg, Germany. 10. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Abstract
BACKGROUND: The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL). METHODS: Patients were randomly assigned to six cycles of CHOP-like regimens with or without rituximab. RESULTS: Of 824 patients enrolled, 87 had PMBCL and 627 other types of DLBCL. Rituximab increased the rates of complete remission (unconfirmed) in both PMBCL (from 54% to 80%, P = 0.015) and DLBCL (from 72% to 87%, P < 0.001). In PMBCL, rituximab virtually eliminated progressive disease (PD) (2.5% versus 24%, P < 0.001), whereas without rituximab, PD was more frequent in PMBCL than in DLBCL (24% versus 10%, P = 0.010). With a median observation time of 34 months, 3-year event-free survival (EFS) was improved by rituximab for PMBCL (78% versus 52%, P = 0.012) and for DLBCL (81% versus 61%, P < 0.001). Overall survival benefit was similar for DLBCL (93% versus 85%, P < 0.001) and PMBCL (89% versus 78%, P = 0.158). CONCLUSION: In young patients with PMBCL (age-adjusted International Prognostic Index 0-1), rituximab added to six cycles of CHOP-like chemotherapy increases response rate and EFS to the same extent as other DLBCL. The combination of rituximab with CHOP chemotherapy is an effective treatment in PMBCL with good prognosis features.
RCT Entities:
BACKGROUND: The aim of this subgroup analysis of the Mabthera International Trial Group study was to evaluate the impact of chemotherapy and rituximab in primary mediastinal B-cell lymphoma (PMBCL) in comparison to other diffuse large B-cell lymphoma (DLBCL). METHODS:Patients were randomly assigned to six cycles of CHOP-like regimens with or without rituximab. RESULTS: Of 824 patients enrolled, 87 had PMBCL and 627 other types of DLBCL. Rituximab increased the rates of complete remission (unconfirmed) in both PMBCL (from 54% to 80%, P = 0.015) and DLBCL (from 72% to 87%, P < 0.001). In PMBCL, rituximab virtually eliminated progressive disease (PD) (2.5% versus 24%, P < 0.001), whereas without rituximab, PD was more frequent in PMBCL than in DLBCL (24% versus 10%, P = 0.010). With a median observation time of 34 months, 3-year event-free survival (EFS) was improved by rituximab for PMBCL (78% versus 52%, P = 0.012) and for DLBCL (81% versus 61%, P < 0.001). Overall survival benefit was similar for DLBCL (93% versus 85%, P < 0.001) and PMBCL (89% versus 78%, P = 0.158). CONCLUSION: In young patients with PMBCL (age-adjusted International Prognostic Index 0-1), rituximab added to six cycles of CHOP-like chemotherapy increases response rate and EFS to the same extent as other DLBCL. The combination of rituximab with CHOP chemotherapy is an effective treatment in PMBCL with good prognosis features.
Authors: Vitaliana DE Sanctis; Alice DI Rocco; Maria Christina Cox; Maurizio Valeriani; Francesca Perrone Congedi; Dimitri Anzellini; Maria Massaro; Gianluca Vullo; Giuseppe Facondo; Flavia DE Giacomo; Marco Alfò; Daniela Prosperi; Patrizia Pizzichini; Sabrina Pelliccia; Agostino Tafuri; Maurizio Martelli; Mattia Falchetto Osti Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Theodoros P Vassilakopoulos; Gerassimos A Pangalis; Andreas Katsigiannis; Sotirios G Papageorgiou; Nikos Constantinou; Evangelos Terpos; Alexandra Zorbala; Effimia Vrakidou; Panagiotis Repoussis; Christos Poziopoulos; Zacharoula Galani; Maria N Dimopoulou; Stella I Kokoris; Sotirios Sachanas; Christina Kalpadakis; Evagelia M Dimitriadou; Marina P Siakantaris; Marie-Christine Kyrtsonis; John Dervenoulas; Meletios A Dimopoulos; John Meletis; Paraskevi Roussou; Panayiotis Panayiotidis; Photis Beris; Maria K Angelopoulou Journal: Oncologist Date: 2012-01-26
Authors: Marta Bruno Ventre; Andrés J M Ferreri; Mary Gospodarowicz; Silvia Govi; Carlo Messina; David Porter; John Radford; Dae Seog Heo; Yeon Park; Giovanni Martinelli; Emma Taylor; Helen Lucraft; Angela Hong; Lydia Scarfò; Emanuele Zucca; David Christie Journal: Oncologist Date: 2014-02-24
Authors: T P Vassilakopoulos; G A Pangalis; S Chatziioannou; S Papageorgiou; M K Angelopoulou; Z Galani; G Kourti; V Prassopoulos; T Leonidopoulou; E Terpos; M N Dimopoulou; S Sachanas; C Kalpadakis; P Konstantinidou; D Boutsis; E Stefanoudaki; L Kyriazopoulou; M P Siakantaris; M-C Kyrtsonis; E Variami; I Kotsianidis; A Symeonidis; E Michali; E Katodritou; G Kokkini; C Tsatalas; H Papadaki; M-A Dimopoulos; V Sotiropoulos; V Pappa; T Karmiris; J Meletis; J Apostolidis; I Datseris; P Panayiotidis; K Konstantopoulos; P Roussou; P Rondogianni Journal: Leukemia Date: 2015-05-14 Impact factor: 11.528
Authors: Santosha Vardhana; Paul A Hamlin; Joanna Yang; Andrew Zelenetz; Craig S Sauter; Matthew J Matasar; Andy Ni; Joachim Yahalom; Craig H Moskowitz Journal: Biol Blood Marrow Transplant Date: 2018-06-15 Impact factor: 5.742